bosentan anhydrous has been researched along with Carcinoma in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bogaard, HJ; Botros, L; Van Nieuw Amerongen, GP; Vonk Noordegraaf, A | 1 |
| Brock, P; Emmrich, J; Fitzner, B; Holzhüter, SA; Jaster, R; Liebe, S; Nizze, H; Sparmann, G | 1 |
2 other study(ies) available for bosentan anhydrous and Carcinoma
| Article | Year |
|---|---|
Recovery from mitomycin-induced pulmonary arterial hypertension.
Topics: Antineoplastic Agents; Anus Neoplasms; Bosentan; Carcinoma; Endothelin Receptor Antagonists; Female; Humans; Hypertension, Pulmonary; Middle Aged; Mitomycin; Sulfonamides | 2014 |
Synergistic growth inhibitory effects of the dual endothelin-1 receptor antagonist bosentan on pancreatic stellate and cancer cells.
Topics: Animals; Bosentan; Carcinoma; Cell Line, Tumor; Coculture Techniques; Collagen; Endothelin Receptor Antagonists; Endothelin-1; Fibrosis; Organotin Compounds; Pancreas; Pancreatic Neoplasms; Pancreatitis, Chronic; Rats; Receptors, Endothelin; Sulfonamides | 2009 |